Compare prices and buy Noopept from 4 research peptide vendors - also called suppliers or sources. Updated daily.
N-phenylacetyl-L-prolylglycine ethyl ester, a capped dipeptide ester also known by its international nonproprietary name omberacetam and its code GVS-111, designed as a dipeptide analog of the nootropic piracetam. Rodent studies by its developers suggest it acts as a prodrug of the cyclic dipeptide cycloprolylglycine, which enhanced AMPA receptor currents in rat neurons, and noopept raised NGF and BDNF expression in rat hippocampus. It is not FDA-approved, and an FDA warning letter has treated a noopept powder sold in the US as an unapproved new drug.
For research purposes only. Not medical advice.
Noopept is N-phenylacetyl-L-prolylglycine ethyl ester, C17H22N2O4, which PubChem lists at a molecular weight of 318.4. Its core is the dipeptide prolylglycine with both ends capped, a phenylacetyl group on the proline nitrogen and an ethyl ester on the glycine carboxyl. That makes it a capped dipeptide ester, two amino acids long, rather than a peptide drug in the usual sense. Its international nonproprietary name is omberacetam and its development code is GVS-111, and vendor titles using either name, or "Noopept (Omberacetam)", map to this row. PeptideScouter catalogues it under Nootropic & Neurological, beside other Russian-developed compounds such as Semax and Emoxypine Succinate, because the research-peptide vendors it indexes sell it alongside their peptides.
Noopept came out of a dipeptide drug-design program at the V.V. Zakusov Institute of Pharmacology in Moscow. Its developers describe the method as turning a known non-peptide drug into a dipeptide topological analog, and name noopept as the dipeptide analog of the nootropic piracetam (Gudasheva, Ostrovskaya and Seredenin, Current Pharmaceutical Design, 2018). A 2014 paper from the same group points to the shared features: both molecules contain a pyrrolidine ring with an acylated nitrogen, an amide group and a glycine fragment.
US patent 5,439,930, issued in 1995 with Seredenin, Voronina, Gudasheva and Ostrovskaya among its inventors, claims N-phenylacetyl-L-prolylglycine ethyl ester within a broader series of N-acylprolyl dipeptides that it describes as facilitating learning and memory.
Every mechanistic finding below is preclinical, and most come from the developers' own laboratories.
In rats, Gudasheva and colleagues (European Journal of Drug Metabolism and Pharmacokinetics, 1997) could not detect noopept itself in brain tissue an hour after injection, while cycloprolylglycine rose 2.5-fold, and plasma and brain enzymes formed cycloprolylglycine from noopept in vitro. They concluded that noopept is a prodrug of cycloprolylglycine, a cyclic dipeptide that is also present in untreated rat brain.
Later work from the group links that metabolite and noopept to glutamate and growth-factor signalling:
The developers also report that a screen of noopept against more than 100 known receptors, run by the French contract laboratory CEREP, "did not lead to the expected identification of the primary targets" (Vakhitova and colleagues, Acta Naturae, 2016).
The clinical record comes from Russia and is small. Neznamov and Teleshova, of the Zakusov Institute's clinical psychopharmacology laboratory, compared noopept with piracetam in patients with mild cognitive disorders due to vascular or traumatic brain disease (Neuroscience and Behavioral Physiology, 2009). A 2014 paper by the developers cites it as Phase III and post-registration evidence in such patients.
Amelin and colleagues (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2011) reported an open prospective study that included 60 patients after stroke. Mini-Mental State Examination scores and verbal association tests improved significantly after two months in the treated group compared with controls. The study was open, and its abstract describes no randomization.
ClinicalTrials.gov returns no study of noopept, omberacetam or GVS-111 as of November 3, 2026.
Noopept has not entered the US compounding-list process that decided the status of several peptides in this category.
Only in a narrow sense. Noopept is N-phenylacetyl-L-prolylglycine ethyl ester, the dipeptide prolylglycine with a phenylacetyl group capping one end and an ethyl ester capping the other, at a molecular weight of 318.4. It was designed at the Zakusov Institute of Pharmacology in Moscow as a dipeptide analog of the nootropic drug piracetam, not as a peptide drug in the usual sense. PeptideScouter catalogues it with the nootropic and neurological compounds because research-peptide vendors sell it alongside their peptides.
In a 1997 rat study by its developers, noopept itself was not detected in the brain an hour after injection, while the level of cycloprolylglycine, a cyclic dipeptide also present in untreated rat brain, rose 2.5-fold, and plasma and brain enzymes formed cycloprolylglycine from noopept in vitro. The authors concluded that noopept is a prodrug of cycloprolylglycine. A 2016 study by the same group found that cycloprolylglycine enhanced AMPA receptor currents in rat neurons. All of these findings are preclinical.
They are different compounds with a shared design. Piracetam is a pyrrolidone drug, and noopept was built by the Zakusov Institute group as its dipeptide analog, so both contain a pyrrolidine ring with an acylated nitrogen, an amide group and a glycine fragment. In rats noopept is metabolized to cycloprolylglycine, a cyclic dipeptide, and its developers report a different spectrum of pharmacological activity from piracetam. On FDA's 503A and 503B bulk-substance nominations lists piracetam sits in Category 3, nominated without adequate support, while noopept does not appear on either list.
No. Drugs@FDA returned no application for noopept or its international nonproprietary name, omberacetam, as of November 3, 2026, and neither FDA's 503A nor its 503B bulk-substance nominations list names it. In a February 2022 warning letter, FDA treated a noopept powder sold online with claims about memory and Alzheimer's disease as an unapproved new drug.
PeptideScouter computes a price per milligram only for vials labelled by mass. As of November 2026, PeptideScouter's noopept listings are capsules, tablets and raw powder rather than vials, so they appear in the price table but on no per-milligram ranking.
Noopept is sold by 4 research peptide vendors indexed on PeptideScouter, with 5 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 4 indexed research peptide vendors currently have Noopept in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing Noopept publish a PeptideScouter code, worth 10% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
4 research peptide vendors currently list Noopept on PeptideScouter. We track 5 listings across size and kit variants.
Noopept's CAS Registry Number is 157115-85-0. It is also sold as Omberacetam, Noopept (Omberacetam), GVS-111.
